press conference – 2015 results - fresenius · press conference – 2015 results february 24,...

PRESS CONFERENCE – 2015 RESULTS

February 24, 2016 │ Bad Homburg v.d.H. │ www.fresenius.com

2017 net income target achieved two years early

Continued strong growth expected

25% dividend increase

Outstanding development at Fresenius Kabi

Press Conference – 2015 Results, Fresenius SE & Co. KGaA © Copyright, February 24, 2016

12th consecutive record year: Double-digit increases in sales and net income

FRESENIUS GROUP: FINANCIAL RESULTS

cc = constant currency EBIT and net income before one-time items

Sales EBIT Net income

FY/2015 €27,626 m €3,958 m €1,423 m

Growth (constant currency)

9% 13% 21%

Growth (actual rates) 19% 25% 31%


7,9

10,8 11,4 12,3

14,2

16,0 16,4

19,3 20,3

23,2

27,6

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

€bn

222

330 410

450 514

660

770

938

1.051 1.086

1,423

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

€m


FRESENIUS GROUP: NEW SALES AND EARNINGS RECORDS

Sales Net Income

Net income before one-time items CAGR = ∅ annual growth rate

FRESENIUS GROUP: DIVIDEND DEVELOPMENT AND TOTAL SHAREHOLDER RETURN


23rd consecutive dividend increase Total Return: Fresenius outperforms DAX index

Source: Bloomberg; dividends reinvested

Dividend growth aligned to EPS growth Payout ratio: 21%

0 4 8 12 16 20 24

DAX

Freseniusshare ~20% p.a.

~7% p.a.

%

Compounded annual total return Dec 31, 2005 − Dec 31, 2015

0.02

0.16 0.19

0.22 0.23 0.25 0.29

0.32

0.37

0.42 0.44

0.55

'93 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15

2015: Proposal

€ 2015

+25%

FY/2015

Growth FY YoY

Sales EBIT

US$16,738 m US$2,327 m

6% 3%

Sales EBIT

€5,950 m €1,189 m

16% 36%

Sales EBIT

€5,578 m €640 m

6% 16%

Sales EBIT

€1,118 m €64 m

7% 8%

FRESENIUS GROUP: FINANCIAL RESULTS BY BUSINESS SEGMENT


EBIT partly before special items

FRESENIUS KABI: STRONG GROWTH IN ALL AREAS


- 8% organic sales growth, 21% EBIT growth in constant currency

- Growth driver North America: persisting drug shortages and new product launches

- High double-digit growth rates in emerging markets

Growth Investing in Quality

Sales Distribution by Region 2015

Europe 36%

North America 35%

Emerging markets 29%

- Ultramodern IV production plant in Melrose Park, USA plant put into operation

⇒ Technology transfers to additional plants

- Reliably high product quality improves Fresenius Kabi’s competitive position

⇒Benefits patients and the company

As of Dec 31, 2015

FRESENIUS HELIOS: INTEGRATION PROCESS COMPLETED, TARGETING CONTINUED GROWTH


- 4% organic sales increase in Q4/15, driven by solid admission growth

- Continued favorable reimbursement environment; DRG inflator set at 2.95%

- Hospital network “Wir für Gesundheit” with more than 5,000 PlusCards in use as of Jan 31, 2016

- Privatization trend ongoing; acquisition of 500-bed hospital in February 2016

Growth Largest network with 111 hospitals

~ 34,000 beds

~ 1.3 million inpatient admissions

~ 3.4 million outpatient admissions

FRESENIUS VAMED: BALANCED PORTFOLIO PROVIDES STABLE GROWTH


- €904 m order intake at all-time high, providing a solid basis for FY/2016

- Further expansion of geographic presence, primarily in emerging and developing countries

- Revenue share of service business expected to increase mid to long-term

Growth Sustained Double-Digit Growth

23 26

30 36

41 44

51 55

59 64

0

10

20

30

40

50

60

70

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

392 408 524

618 713 737

846

1,020 1,042 1,118

0

200

400

600

800

1.000

1.200

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

€m

Service Business Project Business

49%

33%

51%

67%

2015

2011

Expansion of Service Business

% of total sales €m

CAGR = ∅ annual growth rate

FRESENIUS GROUP: 2016 FINANCIAL GUIDANCE


Sales growth constant currency

6% ‒ 8%

Net income growth constant currency

8% ‒ 12%

Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before special items

FRESENIUS GROUP: 2016 FINANCIAL OUTLOOK BY BUSINESS SEGMENT


Sales growth (constant currency) Net income growth

7% – 10% 15% – 20%

Sales growth (organic) EBIT (constant currency)

low single-digit Roughly flat

Sales growth (organic) EBIT

3% – 5% €670 – 700 m

Sales growth (organic) EBIT growth

5% – 10% 5% – 10%

FRESENIUS GROUP: NEW MID-TERM GROWTH TARGETS


2019:

€36 - 40 billion in sales

€2.0 - 2.25 billion in net income

- At comparable exchange rates

- Without large acquisitions

STRONG GROWTH EVEN WITHOUT LARGE ACQUISITIONS


2005 2015

€7.9 bn

€27.6 bn

Fresenius Group Sales

2019e

€2-2.25 bn

Within a 5-year period

NEW MID-TERM GUIDANCE: CONTINUED STRONG NET INCOME GROWTH EXPECTED


2014

€1.09 bn

2009

€0.5 bn

2019e

€2-2.25 bn

2x

Within a 10-year period

4x


SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

PRESS CONFERENCE – 2015 RESULTS

February 24, 2016 │ Bad Homburg v.d.H. │ www.fresenius.com

press conference – 2015 results - fresenius · press conference – 2015 results february 24,...

Documents